UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/508,893	01/26/2005	Scott K. Thompson	P51330	9702	
20462 7590 08/23/2007 SMITHKLINE BEECHAM CORPORATION CORPORATE INTELLECTUAL PROPERTY-US, UW2220 P. O. BOX 1539 KING OF PRUSSIA, PA 19406-0939			EXAMINER		
			OH, TAYLOR V		
			ART UNIT	PAPER NUMBER	
KING OF TROSSIA, TA 19400-0939		1625			
			MAIL DATE	DELIVERY MODE	
			08/23/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application No.	Applicant(s)			
		10/508,893	THOMPSON ET AL.			
Office Action Summary		Examiner	Art Unit			
		Taylor Victor Oh	1625			
Period fo	The MAILING DATE of this communication app or Reply	ears on the cover sheet wit	h the correspondence address			
WHIC - Exter after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DANSIONS of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. or period for reply is specified above, the maximum statutory period or to reply within the set or extended period for reply will, by statute reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNIC 36(a). In no event, however, may a re vill apply and will expire SIX (6) MON <sup>*</sup> , cause the application to become AB	ATION. ply be timely filed  HS from the mailing date of this communication.  NDONED (35 U.S.C. § 133).			
Status						
1)⊠	Responsive to communication(s) filed on 25 M	ay 2007.				
2a) <u></u>	This action is <b>FINAL</b> . 2b) This action is non-final.					
3)□	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
	closed in accordance with the practice under E	x parte Quayle, 1935 C.D.	11, 453 O.G. 213.			
Dispositi	ion of Claims					
5) 6) 7)	Claim(s) 1-23,25-47 and 56-58 is/are pending 4a) Of the above claim(s) is/are withdray Claim(s) is/are allowed. Claim(s) is/are rejected. Claim(s) is/are objected to. Claim(s) 1-23, 25-47, 56-58 are subject to rest	vn from consideration.	irement.			
Applicati	ion Papers					
10)	The specification is objected to by the Examine The drawing(s) filed on is/are: a) according a line of the Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct The oath or declaration is objected to by the Examine	epted or b) objected to be drawing(s) be held in abeyandion is required if the drawing(	ce. See 37 CFR 1.85(a). s) is objected to. See 37 CFR 1.121(d).			
Priority (	ınder 35 U.S.C. § 119					
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>						
	t(s)  e of References Cited (PTO-892)  of Oraftsperson's Patent Drawing Review (PTO-948)		ummary (PTO-413) /Mail Date			
3) Inform	mation Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date		formal Patent Application			

Art Unit: 1625

## The Lack of Unity

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claims 1-23 is drawn to the none-hetero containing various aliphatic and cyclic compounds following compound formula (I) as disclosed below

Group II, claims 1-21, and 23, is drawn to the hetero cyclic compound following compound formula (I) as disclosed below:

Art Unit: 1625

Group III, claims 25-47 is drawn to the method of the prevention or treatment of an LXR mediated disease by using non-hetero compound containing various aliphatic and cyclic compounds following compound formula (I) as disclosed below:

Group IV, claims 25-41, 43-47, is drawn to the method of the prevention or treatment of an LXR mediated disease by using hetero compounds containing various heterocylic compounds following compound formula (I) as disclosed below:

following compound formula (I) as disclosed below:

Application/Control Number: 10/508,893

Art Unit: 1625

I. The inventions listed as Groups do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

the international application shall relate to one invention only or to a group of inventions so linked as to form a single general inventive concept (" requirement of unity of invention").

PCT Rule 13.2 states "Where a group of inventions is claimed in one and the same international application, the requirement of unity of invention referred to in Rule 13.1 shall be fulfilled only when there is a technical relationship among those inventions involving one or more of the same or corresponding special technical features. The expression "special technical features" shall mean those technical features that define a contribution which each of the claimed inventions, considered as a whole, makes over the prior art.

Art Unit: 1625

In the instant case, the invention II is related to the side chain group of hetero cylic compounds of formula (I), whereas the invention I is related to the side chain non-hetero of the formula (I).

Page 5

The heterocylic radical group in Group II has a chemical structure and atoms in the ring, different from the non-heteroaryl radical group in Group I since each will exhibit a chemically different activity respectively. Each invention has a different use and effect due to the unrelated substituent attached to the core of the compounds. Therefore, there is no special technical feature required in Group II. There is no single general inventive concept and no unity of invention for the method or the processes as defined in 37 CFR 1.475.

In the instant case, the invention of Group of the invention I is related to the side chain non-hetero compounds of the formula (I), whereas the invention IV is related to the method of the prevention or treatment of an LXR mediated disease by using hetero compounds containing various heterocylic compounds following compound formula (I); they are different to each other because Schulman et al (US 6,924,311) teaches the use of LXR selective agonist compounds different from the Group of the invention I. Therefore, they are unrelated to each other; Group IV is not directly related to the Group I.

Art Unit: 1625

37 CFR 1.475 states that a national stage application containing claims to different categories of invention will be considered to have unity of invention if the claims are drawn only to one of the following combination of categories:

- a. A product and a process specially adapted for the manufacture of said product; or
- b. A product and a process of use of said product; or
- c. A product, a process specially adapted for the manufacture of the said product, and a use of the said product; or
- d. A process and an apparatus or means specially designed for carrying out the said process; or
- e. A product, a process specially adapted for the manufacture of the said product, and an apparatus or means specially designed for carrying out the said process.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Art Unit: 1625

II. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(l).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Taylor Victor Oh whose telephone number is 571-272-0689. The examiner can normally be reached on 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres can be reached on 571-272-0867. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

TAYLOR VICTOR OH PRIMARY EXAMINER

var

8/20/09

\*\*\*